glp-1 weight loss drug market news today Glucagon-Like Peptide (GLP)-1 Agonists Drugs Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and Pfizer Poll: 1 in 8 Adults
Description
You could also download a reminder app on your phone
PlexusDx supports precision wellness by helping patients understand their GLP-1 pathway predispositions and connect with providers who can tailor recommendations
The study also found that adults taking a GLP-1 had an increased risk for interstitial nephritis, a type of kidney condition that Al-Aly says is almost like an allergic reaction that the kidney mounts against certain drugs. He says more long-term studies are needed to better understand the risks and benefits of prolonged use
Han J, Lee WJ, Hur KY, Cho JH, Lee BW, Park CY
The analysis revealed distinct age-related patterns in adverse event profiles
The medications covered include semaglutide (Wegovy), liraglutide (Saxenda) and tirzepatide (Zepbound)
